长链非编码RNA CCAT1可作为肝细胞癌血浆标志物并预测其治疗效果

摘要/Abstract

摘要： 目的本研究旨在评价长链非编码RNA(lncRNA)结肠癌相关转录因子1(CCAT1)在肝细胞癌(HCC)患者血液中的表达水平, 及其介入或射频治疗前后的变化, 探讨其作为HCC的诊断或预后标志物的可能性。方法收集66例HCC患者及50例健康成人血液标本, 其中37例HCC患者经介入或射频治疗, 同时收集治疗后1个月左右血液标本, 应用qRT-PCR方法分别检测HCC患者和健康成人对照组血液中CCAT1表达水平, 比较了37例HCC患者介入或射频治疗后的CCAT1表达水平。结果 CCAT1在HCC患者血液中的表达水平高于正常对照组(P=0.016), 其ROC曲线下面积为0.782(95%CI:0.692~0.873, P<0.001), 对HCC的诊断有一定的价值。37例HCC患者经射频消融或肝动脉介入治疗后血浆中CCAT1表达水平较治疗前下降(P=0.003)。临床病例特征分析发现, 血浆中CCAT1的表达水平越高则HCC患者的BCLC分期越高。结论本研究显示CCAT1在HCC患者血浆中高表达, 可作为HCC的血浆标志物, 并可预测其治疗效果。

关键词: 肝细胞癌, 长链非编码RNA, 血浆, 肿瘤标志物, CCAT1

Abstract: Objective To assess the expression level of long non-coding ribose nucleic acid (lnc RNA) colon cancer associated transcript-1 (CCAT1) in the peripheral blood of patients with hepatocellular carcinoma (HCC) and its changes before and after interventional or radiofrequency treatment, and to explore its potential as a diagnostic or prognostic biomarker for HCC.Methods Blood samples were collected from 66 HCC patients and 50 healthy controls, among whom 37 HCC patients received interventional or radiofrequency treatment. Reverse-transcription polymerase chain reaction was used to detect the CCAT1 levels. The expression levels of CCAT1 were compared between HCC patients and healthy controls, as well as before and 1 month after intervention or radiofrequency therapy in HCC patients. Results The level of CCAT1 was significantly higher in HCC patients than that in healthy controls (P=0.016). The area under the receiver operating characteristic (ROC) curve of CCAT1 for the diagnosis HCC was 0.782 (95% confidence interval: 0.692-0.873, P<0.001). The expression level of CCAT1 of 37 patients with HCC was decreased after radiofrequency ablation or interventional treatment (P=0.003). High expression of plasma CCAT1 was significantly associated with advanced Barcelona Clinic Liver Cancer (BCLC) stage.Conclusion The expression level of CCTA1 can be used as a noninvasive biomarker for HCC and help to predict therapeutic efficacy.

Key words: Hepatocellular carcinoma, Long non-coding ribose nucleic acid, Colon cancer associated transcript-1, Plasma, Biomarker

张彬彬, 郁皓, 曹斐, 吴晓霞, 单永锋, 王昊楠, 刘慧. 长链非编码RNA CCAT1可作为肝细胞癌血浆标志物并预测其治疗效果[J]. 肝脏, 2021, 26(4): 392-394.

ZHANG Bin-bin, YU Hao, CAO Fei, WU Xiao-xia, SHAN Yong-feng, WANG Hao-nan, LIU Hui. Long non-coding RNA CCAT1 as a plasma biomarker for hepatocellular carcinoma can be used to predict the therapeutic effect[J]. Chinese Hepatolgy, 2021, 26(4): 392-394.

参考文献

[1] Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology, 1998, 27:273-278.
[2] Zong W, Feng W, Jiang Y, et al. Evaluating the diagnostic and prognostic value of serum long non-coding RNA CTC-497E21.4 in gastric cancer. Clin Chem Lab Med, 2019, 57:1063-1072.
[3] Zheng ZK, Pang C, Yang Y, et al. Serum long noncoding RNA urothelial carcinoma-associated 1: A novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Int Med Res, 2018, 46:348-356.
[4] Zhao W, Song M, Zhang J, et al. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. Int J Clin Exp Pathol, 2015, 8:14131-14140.
[5] Huang L, Wang Y, Chen J, et al. Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma. Cell Death Dis, 2019, 10:513.
[6] Hashad D, Elbanna A, Ibrahim A, et al. Evaluation of the Role of Circulating Long Non-Coding RNA H19 as a Promising Novel Biomarker in Plasma of Patients with Gastric Cancer. J Clin Lab Anal, 2016, 30:1100-1105.
[7] Tantai J, Hu D, Yang Y, et al. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol, 2015, 8:7887-7895.
[8] Ye Z, Zhou M, Tian B, et al. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med, 2015, 8:3707-3715.
[9] Yang F, Xue X, Bi J, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol, 2013, 139:437-445.
[10] Zhu H, Zhou X, Chang H, et al. CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion. Int J Clin Exp Pathol, 2015, 8:5427-5434.
[11] Deng L, Yang SB, Xu FF, et al. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. J Exp Clin Cancer Res, 2015, 34:18.
[12] Huang JL, Cao SW, Ou QS, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma. Mol Cancer, 2018, 17:93.
[13] Sun J, Hu J, Wang G, et al. LncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and epithelial-mesenchymal transition in colorectal cancer. J Exp Clin Cancer Res, 2018, 37:106.
[14] Wu Y, Hu L, Liang Y, et al. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer, 2017, 16:150.
[15] Guo J, Ma Y, Peng X, et al. LncRNA CCAT1 promotes autophagy via regulating ATG7 by sponging miR-181 in hepatocellular carcinoma. J Cell Biochem, 2019, 120:17975-17983.